Measurement
Crown-rump length is the measurement of the length of human embryos and fetuses from the top of the head (crown) to the bottom of the buttocks (rump). It is typically determined from ultrasound imagery and can be used to estimate gestational age. Until two years old, recumbent length is used to measure infants. Length measures the same dimension as height, but height is measured standing up while the length is measured lying down. In developed nations, the average total body length of a newborn is about 50 cm (20 in), although premature newborns may be much smaller. Standing height is used to measure children over two years old and adults who can stand without assistance. Measure is done with a stadiometer. In general, standing height is about 0.7 cm (0.28 in) less than recumbent length.Surrogate height measurements are used when standing height and recumbent length are impractical. For sample Chumlea equation use knee height as indicator of stature. Other techniques include: arm span, sitting height, ulna length, etc. See also
Anthropometry, the measurement of the human individual
Body weight
Economics and Human Biology (academic journal)
History of anthropometry
Human physical appearance
Human variability
Pygmy peoples

Citations
General bibliography
Grandjean, Etienne (1987). Fitting the Task to the Man: An Ergonomic Approach. London, UK: Taylor & Francis. ISBN 978-0-85066-192-7. (for heights in U.S. and Japan)
Eurostat Statistical Yearbook 2004. Luxembourg: Eurostat. 2014. ISBN 978-92-79-38906-1. (for heights in Germany)
Netherlands Central Bureau for Statistics, 1996 (for average heights)
Ogden, Cynthia L.; Fryar, Cheryl D.; Carroll, Margaret D. & Flegal, Katherine M. (27 October 2004).
This includes urine organic acid analysis, looking for glutaric acid and 3-hydroxyglutaric acid. Plasma and urine acylcarnitine analysis can also be informative. Molecular analysis, including gene sequencing and copy number analysis of GCDH, can be performed to confirm the diagnosis. Molecular testing can also provide information for family planning and prenatal testing, if desired. Treatment
Correction of secondary carnitine depletion
Like many other organic acidemias, GA1 causes carnitine depletion. Whole-blood carnitine can be raised by oral supplementation. However, this does not significantly change blood concentrations of glutarylcarnitine or esterified carnitine, suggesting that oral supplementation is suboptimal in raising tissue levels of carnitine. Clinical nutrition researchers have likewise concluded that oral carnitine raises plasma levels but does not affect those in muscles, where most of it is stored and used.In contrast, regular intravenous infusions of carnitine cause distinct clinical improvements: "decreased frequency of decompensations, improved growth, improved muscle strength and decreased reliance on medical foods with liberalization of protein intake. "Choline increases carnitine uptake and retention. Choline supplements are inexpensive, are safe (probably even in children requiring anticholinergics) and can increase exercise tolerance, truncal tone and general well-being, providing evidence of the suboptimal efficiency of carnitine supplementation alone. Selective precursor restriction
Dietary control may help limit progression of the neurological damage. Lysine
Lysine restriction, as well as carnitine supplementation, are considered the best predictors of a good prognosis for GA1. This excludes, however, patients who already suffered an encephalopathic crisis, for whom the prognosis is more related to the treatment of their acquired disorder (striatal necrosis, frontotemporal atrophy).